Tomahawk, WI 06/06/2014 (Basicsmedia) – MannKind Corporation (NASDAQ:MNKD) is anticipating the approval of its diabetes treatment drug – Afrezza, by July 15, 2014! FDA’s advisory committee earlier recommended the use of this drug to treat Type1 and Type2 Diabetes. However, the regulatory authority delayed its Prescription Drug User Fee Act or PDUFA review by July 15.

MNKD Set To Reach A Pinnacle, Anticipating Afrezza’s Approval!

Speculations are rife that Afrezza is awaiting a mere formal approval from FDA; incidentally the trading activities are fomenting up, and the share prices have reached its 3 year high! Chances abound that MannKind Corporation (NASDAQ:MNKD) shall break its own record of an All-Time-High of 11.11 in the upcoming months.

The Importance Of Afrezza

Afrezza consists of a recombination of the human-insulin-powder formulation. It can be obtained by oral inhalation and shall be absorbed by the patients’ lungs. This drug-device combo shall bear the medicines in cartridges; each cartridge contains 10 or 20 units of Insulin.

The research firm sees minimal risks involved in Afrezza’s approval. Endocrinologists and millions of patients in the US and across the world desperately need Afrezza to treat Type1 Diabetes and reduce hypoglycemia. In the realm of Type2 Diabetes, the drug is quintessential! The advisory committee has high confidence on Afrezza and chimed in that this drug is deemed to have a high adoption rate.

MNKD Sells 101,899 Stocks In 5 Days!

In a strategic move, VP of MannKind Corporation (NASDAQ:MNKD), Juergen Martens lifted quite a few eyebrows by making a tactical move of selling off 76,899 company shares on May 19, 2014 and another 25K shares on May 23! The whopping open market transactions were premeditated so as to signal the investors about the company’s anticipated prospects in the upcoming quarters.

Afrezza Can Turn The Table For MNKD!

MNKD, which has a market capitalization of 3.90 billion, suffered a gross loss of 14 cents/share evaluating to $52.1 million in Q1-2014. However, Afrezza seems to propel its growth; if the drug is approved, the company would reel in abounding profits during FY 2014-15 and beyond!

After a semi-nod from FDA, the MannKind Corporation (NASDAQ:MNKD) has left nearly no stone unturned in propelling trading – consequently, its stock price has shot upwards, and post-approval of Afrezza it might surmount beyond the All-Time-High, amidst astounding trading performances!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.